ReviewEuropean geriatric medicine2024
Invasive meningococcal disease in older adults: current perspectives and call for action.
Review in European geriatric medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Sustained salivary IgG but short-lived IgA responses following primary and booster MenACWY-TT vaccination in older adults.Human vaccines & immunotherapeutics · 2026Trial
- Pediatric invasive meningococcal disease in Türkiye during the post-pandemic period: increased reported cases and predominance of serogroup B and severity determined by a clinical form in a multicenter hospital-based cohort.European journal of pediatrics · 2026Article
- Burden of Invasive Meningococcal Disease: Evolving Epidemiology and Implications for Prevention Policy.Infectious diseases and therapy · 2026Review
- Ongoing Outbreak ofOpen forum infectious diseases · 2026Article
- Nasopharyngeal Carriage of Neisseria meningitidis in 181 Hajj and Umrah Pilgrims in Türkiye: Pre- and Post-Travel Prevalence and Serogroup Distribution n.Medical science monitor : international medical journal of experimental and clinical research · 2026Observational
- Meningococcal Disease in Older Adults: Challenges in Diagnosis and Management.Infectious diseases and therapy · 2026Review
- Invasive Meningococcal Disease-Changes in Epidemiologic Trends and Outcome over 24 Years in a Tertiary Care Hospital from Romania.Pathogens (Basel, Switzerland) · 2025Article
- Need for Invasive Meningococcal Disease Prevention Through Vaccination for Young Children in the Americas.Vaccines · 2025Review
- Long-Term Impacts of Invasive Meningococcal Disease on Survivors and Their Caregivers in the United States and Canada.Infectious diseases and therapy · 2025Review
- Modeling antibody persistence after MenACYW-TT vaccination and comparative analysis with other quadrivalent meningococcal vaccines.Scientific reports · 2025Article
- Immunogenicity of primary and booster MenACWY-TT vaccination in older adults and the importance of IgM.NPJ vaccines · 2025Article
- Current methods in the diagnosis of invasive meningococcal disease.Frontiers in pediatrics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeInvasive meningococcal disease (IMD) is a devastating condition. While most attention is directed towards disease in children and adolescents, IMD poses an important cause of morbidity and mortality in adults ≥60 years. While immunization is a critical component of healthy ageing strategies, meningococcal immunization is not routinely offered to older adults. The aim of this review was to summarize clinical and epidemiological aspects of IMD and available immunization strategies, with a particular focus on disease in older individuals, to emphasize the importance of this rather neglected area.
methodsAn expert working group was established to evaluate clinical and epidemiological data to raise awareness of IMD in older individuals, and develop suggestions to improve the existing burden.
resultsRoutine child and adolescent meningococcal immunization has substantially reduced IMD in these targeted populations. Consequently, prevalence and proportion of IMD among those ≥60 years, mostly unvaccinated, is increasing in developed countries (accounting for up to 25% of cases). IMD-related mortality is highest in this age-group, with substantial sequelae in survivors. IMD due to serogroups W and Y is more prevalent among older adults, often with atypical clinical features (pneumonia, gastrointestinal presentations) which may delay timely treatment.
conclusionsIMD in older adults remains overlooked and greater awareness is required at clinical and societal levels. We encourage clinicians and immunization policy makers to reconsider IMD, with a call for action to remedy existing inequity in older adult access to protective meningococcal immunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.